Supporting Online Material
Total Page:16
File Type:pdf, Size:1020Kb
Supplementary Information for Epigenetic inactivation of oncogenic brachyury (TBXT) by H3K27 histone demethylase controls chordoma cell survival Lucia Cottone, Edward S Hookway, Adam Cribbs, Graham Wells, Patrick Lombard, Lorena Ligammari, Anthony Tumber, Roberto Tirabosco, Fernanda Amary, Tamas Szommer, Catrine Johannson, Paul E. Brennan, Nischalan Pillay, Udo Oppermann, Adrienne M. Flanagan Corresponding authors Adrienne M Flanagan [email protected] and Udo Oppermann [email protected] This PDF file includes: Figs. S1 to S6 Tables S1 to S5 Captions for Datasets S1 to S2 Supplementary text References for SI reference citations Other supplementary materials for this manuscript include the following: Datasets S1 to S2 1 Supplementary Figures Fig. S1. Ligand structure of human KDM6C/UTY in complex with KDOBA67. Crystal structure of UTY/KDM6C in complex with the inhibitor KDOBA67a shows identical ligand binding as KDM6B/GSK-J1. (a) Representation of the ligand binding pocket in KDM6C/UTY (pdb 5A1L, rendered in pink) in complex with KDOBA67a (cyan). Amino acid side-chains lining the active site are depicted as sticks. The position of the catalytic metal ion and water molecules are shown as orange/brown spheres. The 2FoFc electron density map is contoured at 1.0 sigma. (b) KDOBA67 occupies part of the cofactor site in KDM6 enzymes, demonstrated through an overlay of UTY (pdb 5A1L, pink) with KDM6B (grey) in complex with the 2'oxoglutarate cofactor (yellow) (PDB 2XUE). (c) KDOBA67 shows equivalent occupation and residue contacts in the active site of KDM6 enzymes, demonstrated through an overlay of KDM6C/KDOBA67 and KDM6B/GSK-J1 (magenta) (PDB 4ASK) complexes. 2 A DMSO GSK-J4 GSK-J5 KDOBA67 B MUG 72h 100 ** *** s l l e 75 * c f G o e U g a 50 t M *** n e c r e P 25 * *** 0 DMSO GSK-J4 GSK-J5 KDOBA67 t n u UM-Chor 72h o 100 C *** s r l l o e 75 c h f o C e - g a 50 t M n e c U r e P 25 *** 0 DMSO GSK-J4 GSK-J5 KDOBA67 SubG1 S G2 G1 Propidium Iodide C DMSO GSK-J4 GSK-J5 KDOBA67 D MUG 72h 20 s l l **** e c 15 *** + I P G + V U 10 n i x M e n n 5 A e % d i 0 d DMSO GSKJ4 GSKJ5 KDOBA67 o I m u i UmChor 72h d i p 20 **** o s l l r e c r P 15 + I o P h + V 10 C n i - x e *** n M n 5 A U % 0 DMSO GSKJ4 GSKJ5 KDOBA67 Annexin V - APC E F UCH1 48h MUG 48h UM-Chor 48h UCH1 48h MUG 48h UMChor 48h 100 100 100 ** *** ** * 15 10 6 ** * * **** s s s s l l l s l ** s l l l l ** l l l l e e e e 8 e * e c c 75 75 75 c c c c + + + f f I I I f 10 4 o o P P P o * 6 + + + e e e V V V g g g n n n a a i i 50 i 50 a 50 t t t x x x 4 n n n e e e e 5 2 e e n n n c c c n n n r r r e A A A 2 e e P P 25 25 P 25 % % % 0 0 0 ** DMSO GSKJ4 GSKJ5 KDOBA67 DMSO GSKJ4 GSKJ5 KDOBA67 DMSO GSKJ4 GSKJ5 KDOBA67 0 0 0 DMSO GSK-J4 GSK-J5 KDOBA67 DMSO GSK-J4 GSK-J5 KDOBA67 DMSO GSK-J4 GSK-J5 KDOBA67 Fig. S2. H3K27 lysine demethylase inhibitors induce cell cycle arrest and apoptosis in chordoma cell lines. Cell cycle changes (A-B) and cell death analysis (C-D) in response to the compounds after 72 hours of treatment in UM-Chor1 and MUG-Chor1. By 72 hours, there is evidence of apoptosis as determined by an increase in sub- G1 and in AnnexinV-PI positive population in response to GSK-J4 and KDOBA67. Cell cycle changes (E) and cell death analysis (F) in response to the compounds after 48 hours of treatment in UCH1, UM-Chor and MUG- Chor. By 48 hours, there is evidence of G1 arrest as determined by an increase in G1 population and reduction in 3 the S population together with a slight increase AnnexinV-PI positive population in response to GSK-J4 and KDOBA67. Representative histogram/dot plots and quantification of 3 independent experiments, with 3 replicates per condition. *p ≤0.05, **p ≤0.01, ***p ≤0.001, ****p ≤0.0001. 4 A UCH1 B UM-Chor l l l l l l tr O tr O tr tr O O tr tr O O C K C K C C K K C C K K KDM6A KDM6B KDM6A KDM6B C Ctrl KDM6A KO KDM6B KO KDM6A/B KO UCH1 D UM-Chor E Ctrl KDM6A KO KDM6B KO KDM6A/B KO **** 250 n.s. ) n.s m n 200 . 0 9 5 / 0 6 150 5 ( e c n 100 e c e r o 50 u l F 0 Ctrl KDM6A KO KDM6B KO KDM6A/B KO UM-Chor F MUG G Ctrl KDM6A KO KDM6B KO J 400 * TBXT - MUG-Chor H ) **** D 2.0 P m *** A n 0 G 9 300 r 5 e 1.5 / v 0 o 6 5 n ( o 200 i 1.0 e s c s n e r e p c x 0.5 e r 100 e o A u l N F R 0.0 0 m DMSO KDOBA67 Ctrl KDM6A KO KDM6B KO MUG-Chor H I K TBXT - UM-Chor TBXT - UM-Chor H H D D 6 * 1.5 P P A *** A G G r r e e v v 4 1.0 o o n n o o i i s s s s e e r r 2 0.5 p p x x e e A A N N R 0.0 R 0 m m Control KDM6A/B KO DMSO KDOBA67 Fig. S3. CRISPR/Cas9 mediated KDM6A and KDM6B knockout. (A-B) Cleavage assay for UCH1 and UM- Chor for cells transduced with empy-Lenti-Cas9-vector, guideRNA-directed at KDM6A or KDM6B, show efficient gene editing at the predicted site. (C) Bright field images of UCH1 with CRISPR editing of KDM6A/B or both. (D-E) CRISPR/Cas9 knock-out of KDM6A and KMD6B induces cell growth arrest in UM-Chor chordoma cell line. Cell viability and representative images of chordoma cells transduced with empy-Lenti-Cas9-vector, guideRNA-directed towards KDM6A, KDM6B or co-transduced with both. (F-G) In MUG-Chor cell line knockout of KDM6A is sufficient to reduce cell viability as MUG-Chor contains a biallelic deletion of KDM6B (H) as visualised by genome sequencing generated from the ChIP input. (I) Expression of TBXT is reduced in UM-Chor upon double KO of KDM6A/B, as assessed by qPCR. Quantification of 2 independent experiments, with 2 5 replicates per condition. (J-K) Expression of TBXT is reduced in chordoma cell lines as assessed by qPCR. *p ≤0.05, **p ≤0.01, ***p ≤0.001, ****p ≤0.0001. 6 Fig. S4. Methylation profiles of TBXT promoter in a range of solid tumours. Data from the Cancer Tumor Genome Atlas (TCGA) showed that the promoter of TBXT is unmethylated is a variety of malignancies, known not to express TBXT. Low levels of methylation are prominent in cervical squamous cell carcinomas, diffuse B cell lymphomas and adenocarcinomas of the gastrointestinal tract, tumours which are rarely reported to express TBXT protein 7 A B MUG-Chor C MUG-Chor (replicate) D UCH1 E UCH7 Fig. S5. Transcriptomic analysis of chordoma cell lines in response to KDOBA67. (A) PCA plot of all RNA sequencing data for UCH1, UCH7, MUG-Chor, UM-Chor. Two independent datasets were generated for MUG- Chor, and the very close clustering shows high reproducibility of the data. (B-E) Volcano plot summarising differential expression in chordoma cells following treatment with KDOBA67. 8 A B C D MUG 0.6 0.20 UM-Chor INHBE H Mt1X H H H D D D D P 15 60 P 0.15 P P A **** 0.4 A A A G G G G r r e e r *** r TBXT v v e e 0.10 o v o 10 v 40 ATF4 o 0.2 o n n TBXT o n n o i DDIT3 i o o s s i i 0.05 ATF4 s s s s e INHBE e s s r r DDIT3 e e p r r 5 20 p x x p p 0.0003 INHBE e e x x e e e e 0.0003 n n A A e 0.0002 e N N G 0.0002 G R 0 R 0 m DMSO KDOBA67 m DMSO KDOBA67 0.0000 0.0000 0 3 6 24 48 0 3 6 24 48 Time (hours) Time (hours) E DDIT3 F ATF4 DDIT3 G ATF4 DDIT3 H H H H H D D D D D 8 8 40 3 10 P P P P P **** * A A A A A O O O O O * * G ** * G G **** *** G G S S S * * S S r r r r 8 r M M M M e e M 6 e e 30 e 6 D v v D D v D v v D 2 o o o o o o o o o o t t t t 6 n t n n n n o d o d o d o d i i o d i 4 i e e 20 i e 4 e s s e s s s s s s s s i s i s s s i i l l s i 4 l l e e l e e a a r e r a a 1 r r a r p p m p p m m m p r 2 x m x r x r x 2 r 10 x r e o e o e e 2 o o e o n n n n A A n A A A N N N N N R 0 R 0 R R 0 0 R 0 m m 7 7 m O B 7 7 m 7 7 O IB 6 6 7 7 m 7 7 I 6 6 O IB 6 S O IB 6 6 O IB 6 S R A A S 6 R A A S S 6 M S R A A M IS B B R A A R A A D I B B M IS B B D M IS B B M IS B B O O D O O D D D D O O D D O O O O D D K K D D D D K K K K K K K K + + + + + IB B B B B R I I I I S R R R R I IS IS IS IS INHBE INHBE TBXT INHBE TBXT H H H H H D D D D 2.0 15 1.5 D 3 1.5 P P P P P A A A A A O O O O n.s.